The new biopharmaceutical development and manufacturing facility will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs. Fluor’s scope of work included the engineering, procurement, construction management, commissioning, qualification and validation for the facility.

“Fluor’s innovative plant layout and modularized construction approach allowed this facility to be built safely and with capital efficiency,” said Richard Meserole, president of Fluor’s Advanced Technologies & Life Sciences business line. “The project was phased to allow start-up activities to commence as needed to support production timeline.”

Fluor also completed construction of Bayer’s state-of-the-art Single Use Technology biopharmaceutical manufacturing Cell Culture Technology Center (CCTC) in 2021. The CCTC supports Bayer’s teams producing multiple biologic therapies.

The new cell therapy facility is part of a transformation at Bayer's dedicated biotechnology site in Berkeley, California, where the company has invested around €470 million ($500 million) over the past five years. To read more about the operations plans of the facility, see our previous news release.